Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 24-35

  Oberstein, Timo Jan ^a   Spitzer, Philipp ^a   Klafki, Hans Wolfgang ^a,b   Linning, Philipp ^c   Neff, Florian ^a,d   Knölker, Hans Joachim ^c   Lewczuk, Piotr ^a   Wiltfang, Jens ^e   Kornhuber, Johannes ^a   Maler, Juan Manuel ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alzheimer's disease; Astrocytes; A ; BACE; Extracellular; Intracellular; Microglia; N terminally truncated; Neurons; Secretase

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 2 X; AMYLOID BETA PROTEIN 3 X; AMYLOID BETA PROTEIN 4 X; AMYLOID BETA PROTEIN 5 X; BETA SECRETASE 1; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; N [N (3,5 DIFLUOROPHENACETYL)ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; PEPTIDE FRAGMENT; TAU PROTEIN;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROGLIA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SENILE PLAQUE; SUPERNATANT; AMYLOID PLAQUE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CHEMISTRY; CHICK EMBRYO; CYTOLOGY; DRUG EFFECTS; IMMUNOPRECIPITATION; METABOLISM; NERVE CELL; TIME;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ASTROCYTES; BRAIN; CELLS, CULTURED; CHICK EMBRYO; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOPRECIPITATION; MICROGLIA; NEURONS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; TAU PROTEINS; TIME FACTORS;

EID: 84908439707     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.031     Document Type: Article

References (75)

1. Bayer T.A., Wirths O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 2014, 127:787-801.
2. Bien J., et al. The metalloprotease meprin beta generates amino terminal-truncated amyloid beta peptide species. J. Biol. Chem. 2012, 287:33304-33313.
3. Bohme L., et al. Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases. Biol. Chem. 2008, 389:1055-1066.
4. Bouter Y., et al. N-truncated amyloid beta (Abeta) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 2013, 126:189-205.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
6. Braak H., et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
7. Carrodeguas J.A., et al. The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. Neuroscience 2005, 134:1285-1300.
8. Casas C., et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165:1289-1300.
9. Cynis H., et al. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta 2006, 1764:1618-1625.
10. Cynis H., et al. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008, 47:7405-7413.
11. De Kimpe L., et al. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Abeta pathology at the lysosome. Age (Dordr) 2013, 35:673-687.
12. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 2003, 38:9-12.
13. Delacourte A., Defossez A. Alzheimer's disease: tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J. Neurol. Sci. 1986, 76:173-186.
14. Esselmann H., et al. Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38. Neurodegener. Dis. 2004, 1:236-241.
15. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
16. Grundke-Iqbal I., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
17. Guntert A., et al. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143:461-475.
18. Haass C., Selkoe D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993, 75:1039-1042.
19. Haass C., et al. Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J. Neurosci. 1991, 11:3783-3793.
20. Harper J.D., et al. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem. Biol. 1997, 4:951-959.
21. Haussmann U., et al. Analysis of amino-terminal variants of amyloid-beta peptides by capillary isoelectric focusing immunoassay. Anal. Chem. 2013, 85:8142-8149.
22. Herculano-Houzel S. The glia/neuron ratio: how it varies uniformly across brain structures and species and what that means for brain physiology and evolution. Glia 2014, 62(9):1377-1391.
23. Hook V., et al. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol. Chem. 2005, 386:931-940.
24. Howell S., et al. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 1995, 16:647-652.
25. Hu J., et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 2001, 276:47863-47868.
26. Hussain I., et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell. Neurosci. 1999, 14:419-427.
27. Jarrett J.T., et al. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
28. Klafki H.W., et al. Electrophoretic separation of betaA4 peptides (1-40) and (1-42). Anal. Biochem. 1996, 237:24-29.
29. Kuo Y.M., et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001, 276:12991-12998.
30. LeBlanc A.C., et al. Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. J. Neurochem. 1996, 66:2300-2310.
31. LeBlanc A.C., et al. Processing of amyloid precursor protein in human primary neuron and astrocyte cultures. J. Neurochem. 1997, 68:1183-1190.
32. Lee E.B., et al. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem. 2003, 278:4458-4466.
33. Lewczuk P., et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25:273-281.
34. Lewczuk P., et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp. Neurol. 2010, 223:366-370.
35. Liao M.C., et al. Degradation of amyloid beta protein by purified myelin basic protein. J. Biol. Chem. 2009, 284:28917-28925.
36. Linning P., et al. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease. Org. Biomol. Chem. 2012, 10:8216-8235.
37. Maler J.M., et al. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 2007, 7:3815-3820.
38. Maler J.M., et al. Adherence-dependent shifts in the patterns of beta-amyloid peptides secreted by human mononuclear phagocytes. Brain Behav. Immun. 2008, 22:1044-1048.
39. Mandler M., et al. Pyroglutamylated amyloid-beta is associated with hyperphosphorylated tau and severity of Alzheimer's disease. Acta Neuropathol. 2014, 128:67-79.
40. Masters C.L., et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4245-4249.
41. Mattsson N., et al. BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system. PLoS One 2012, 7:e31084.
42. Miller D.L., et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 1993, 301:41-52.
43. Moore B.D., et al. Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res. Ther. 2012, 4:18.
44. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
45. Nagele R.G., et al. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003, 971:197-209.
46. Nussbaum J.M., et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012, 485:651-655.
47. Pacheco-Quinto J., Eckman E.A. Endothelin-converting enzymes degrade intracellular beta-amyloid produced within the endosomal/lysosomal pathway and autophagosomes. J. Biol. Chem. 2013, 288:5606-5615.
48. Portelius E., et al. Mass spectrometric characterization of amyloid-beta species in the 7PA2 cell model of Alzheimer's disease. J. Alzheimers Dis. 2013, 33:85-93.
49. Pruss R.M. Thy-1 antigen on astrocytes in long-term cultures of rat central nervous system. Nature 1979, 280:688-690.
50. Qiu W.Q., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998, 273:32730-32738.
51. Roberds S.L., et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 2001, 10(12):1317-1324.
52. Rufenacht P., et al. Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J. Mass Spectrom. 2005, 40:193-201.
53. Saido T.C. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 1998, 19:S69-S75.
54. Saido T.C., Iwata N. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 2006, 54:235-253.
55. Saido T.C., et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
56. Saido T.C., et al. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 1996, 215:173-176.
57. Schieb H., et al. Structural design, solid-phase synthesis and activity of membrane-anchored beta-secretase inhibitors on Abeta generation from wild-type and Swedish-mutant APP. Chemistry 2010, 16:14412-14423.
58. Schieb H., et al. Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. J. Biol. Chem. 2011, 286:33747-33758.
59. Schilling S., et al. Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. J. Neurochem. 2008, 106:1225-1236.
60. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J. Alzheimers Dis. 2001, 3:75-80.
61. Sergeant N., et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 2003, 85:1581-1591.
62. Sevalle J., et al. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J. Neurochem. 2009, 109:248-256.
63. Smith P.K., et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
64. Struhl G., Adachi A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol. Cell 2000, 6:625-636.
65. Sun B., et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 2008, 60:247-257.
66. Takeda K., et al. Amino-truncated amyloid beta-peptide (Abeta5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J. 2004, 18:1755-1757.
67. Thal D.R., et al. The development of amyloid beta protein deposits in the aged brain. Sci. Aging Knowl. Environ. 2006, re1.
68. Tung J.S., et al. Design of substrate-based inhibitors of human beta-secretase. J. Med. Chem. 2002, 45:259-262.
69. Van Nostrand W.E., Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999, 38:11570-11576.
70. Vandermeeren M., et al. The functional gamma-secretase inhibitor prevents production of amyloid beta 1-34 in human and murine cell lines. Neurosci. Lett. 2001, 315:145-148.
71. Vassar R., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
72. Veeraraghavalu, et al. Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of β-amyloid by cells other than excitatory neurons. J. Neurosci. 2014, 34(10):3668-3673.
73. Wang R., et al. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. J. Biol. Chem. 1996, 271:31894-31902.
74. Wiltfang J., et al. Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis 1997, 18:527-532.
75. Wiltfang J., et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002, 81:481-496.